This article was originally published in Start Up
Having focused largely on the drug component of drug-eluting stents, most companies developing the next wave of bioabsorbable stents are working with the same biopolymers. Theracardia, however, begins life with a portfolio of novel biopolymers that inherently have the potential to avoid inflammation in the body, are bioabsorbable and can be engineered to achieve specific biological effects. The company is validating its platform in a stent biocoating in preparation for developing its own improved bioabsorbable stent, one that, it hopes, will promote rapid endothelialization and reduce restenosis without incorporating a drug.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Eyes Still Have It," features profiles of Alacrity Biosciences, Eyeon Therapeutics, Mobius Therapeutics and OcuCure Therapeutics. Plus these Start-Ups Across Health Care: CyberHeart, GlycoVaxyn, TheraCardia and Vicus Therapeutics.
With a record attendance last month in Barcelona, the annual EuroPCR meeting gathered cardiologists from around the globe for live training sessions, challenging case reviews, trial updates, and data on rapidly evolving new technologies. Drug-eluting stents were high on the agenda with interesting data, but transcatheter heart valve replacement also generated significant interest with packed sessions and busy booths.
Paris-based Arterial Remodeling Technologies is developing a bioabsorbable stent that may not require the use of anti-inflammatories.